46
Participants
Start Date
October 12, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
September 30, 2027
Nivolumab [Opdivo]
Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
RECRUITING
University Hospital Mannheim, Neurology Clinic, Mannheim
NOT_YET_RECRUITING
University Hospital Heidelberg, Neurooncology, Heidelberg
RECRUITING
Katharinenhospital Stuttgart, Stuttgart
RECRUITING
University Hospital Tübingen, Neurooncology, Tübingen
RECRUITING
SLK-Kliniken Heilbronn GmbH Klinik, Heilbronn
RECRUITING
University Hospital Freiburg, Neurosurgery, Freiburg im Breisgau
RECRUITING
Klinikum rechts der Isar/Technische Universität München, München
RECRUITING
University Hospital Ulm, ECTU - Early Clinical Trail Unit, Ulm
RECRUITING
Universitätsklinikum Bonn, Bonn
University Hospital Tuebingen
OTHER